古塞库单抗在中重度斑块状银屑病患者中的免疫原性不具有临床相关性。 - Suppr | 超能文献

相似文献

1

Immunogenicity of Guselkumab Is Not Clinically Relevant in Patients with Moderate-to-Severe Plaque Psoriasis.古塞库单抗在中重度斑块状银屑病患者中的免疫原性不具有临床相关性。

J Invest Dermatol. 2019 Aug;139(8):1830-1834.e6. doi: 10.1016/j.jid.2019.02.018. Epub 2019 Mar 6.

2

Immunogenicity and skin clearance recapture in clinical studies of brodalumab.巴罗达珠单抗临床研究中的免疫原性和皮肤清除恢复。

J Am Acad Dermatol. 2020 Feb;82(2):344-351. doi: 10.1016/j.jaad.2019.05.094. Epub 2019 Jun 5.

3

Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: results from extension phase of the SUPREME study.在中度至重度斑块型银屑病患者中，无论HLA-Cw6状态如何，司库奇尤单抗均显示出高效性：来自SUPREME研究扩展阶段的结果。

Br J Dermatol. 2019 Aug;181(2):413-414. doi: 10.1111/bjd.18013. Epub 2019 May 29.

4

A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis.古塞单抗与阿达木单抗治疗斑块状银屑病的 2 期临床试验。

N Engl J Med. 2015 Jul 9;373(2):136-44. doi: 10.1056/NEJMoa1501646.

5

Successful subcutaneous desensitization in a patient with allergy to ixekizumab.一名对司库奇尤单抗过敏的患者成功进行皮下脱敏治疗。

J Allergy Clin Immunol Pract. 2018 Sep-Oct;6(5):1761-1762. doi: 10.1016/j.jaip.2017.12.036. Epub 2018 Feb 10.

6

Brodalumab in the treatment of moderate to severe psoriasis in patients when previous anti-interleukin 17A therapies have failed.在先前的抗白细胞介素17A疗法失败的患者中，使用布罗达单抗治疗中度至重度银屑病。

J Am Acad Dermatol. 2019 Sep;81(3):857-859. doi: 10.1016/j.jaad.2019.05.007. Epub 2019 May 10.

7

Injection site reactions to ixekizumab - a series of four patients.司库奇尤单抗的注射部位反应——4例患者系列报道

Int J Dermatol. 2020 May;59(5):e137-e139. doi: 10.1111/ijd.14790. Epub 2020 Jan 23.

8

Successful Treatment of Refractory Plaque-Type Psoriasis and Psoriatic Arthritis With Guselkumab and Adalimumab Combination Therapy: A Case Report.古塞库单抗与阿达木单抗联合治疗难治性斑块型银屑病和银屑病关节炎成功：一例报告

J Drugs Dermatol. 2019 Apr 1;18(4):394-396.

9

Guselkumab dosing interval optimization in adult patients with psoriasis: A retrospective, multicenter case series.成年银屑病患者中古塞库单抗给药间隔优化：一项回顾性多中心病例系列研究。

J Am Acad Dermatol. 2020 Dec;83(6):1813-1814. doi: 10.1016/j.jaad.2020.04.025. Epub 2020 Apr 11.

10

Immunogenicity of biotherapy used in psoriasis: the science behind the scenes.生物疗法治疗银屑病的免疫原性：幕后科学。

J Invest Dermatol. 2015 Jan;135(1):31-38. doi: 10.1038/jid.2014.295. Epub 2014 Aug 14.

引用本文的文献

1

Long-Term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic Arthritis. Guselkumab 在银屑病和银屑病关节炎的 11 项 II/III 期临床研究的综合分析：长期安全性。

Drug Saf. 2024 Jan;47(1):39-57. doi: 10.1007/s40264-023-01361-w. Epub 2023 Oct 31.

2

Immunogenicity to biological drugs in psoriasis and psoriatic arthritis.生物药物在银屑病和银屑病关节炎中的免疫原性。

Clinics (Sao Paulo). 2021 Oct 1;76:e3015. doi: 10.6061/clinics/2021/e3015. eCollection 2021.

3

Guselkumab for the Treatment of Palmoplantar Pustulosis: A Japanese Perspective.